QUARTETTE (Ethinyl Estradiol; Levonorgestrel) Patent Expiration, LOE Window & CMS Spending

QUARTETTE (Ethinyl Estradiol; Levonorgestrel) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2029-03-11, 25 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN204061 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-03-11
Last Listed Patent or Exclusivity Date2029-03-11
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors25
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 30.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.